Celularity Inc. is an innovative biotechnology firm dedicated to advancing regenerative medicine through its proprietary cellular products sourced from the placenta. The company is developing a robust pipeline of immunotherapies designed to provide allogeneic off-the-shelf solutions, enhancing treatment efficacy while minimizing complications for patients with cancer and other serious conditions. Backed by a strong management team and strategic collaborations, Celularity is well-positioned to address urgent unmet medical needs, solidifying its role as a pivotal player in the rapidly evolving advanced therapeutics landscape.
| Revenue (TTM) | $26.55M |
| Gross Profit (TTM) | $6.48M |
| EBITDA | $-54.01M |
| Operating Margin | -492.10% |
| Return on Equity | -6367.00% |
| Return on Assets | -30.90% |
| Revenue/Share (TTM) | $1.04 |
| Book Value | $-1.32 |
| Price-to-Book | 9.89 |
| Price-to-Sales (TTM) | 0.79 |
| EV/Revenue | 1.991 |
| EV/EBITDA | -36.78 |
| Quarterly Earnings Growth (YoY) | -61.30% |
| Quarterly Revenue Growth (YoY) | -77.40% |
| Shares Outstanding | $28.95M |
| Float | $18.87M |
| % Insiders | 37.18% |
| % Institutions | 12.77% |
Volatility is currently expanding
FLORHAM PARK, N.J. and ORLANDO, Fla.
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below.
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026.
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company's delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer.
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (“NexGel”), pursuant to which NexGel acquired certain commercial and other assets related to Celularity's biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity's biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform.
